With lorlatinib treatment, the NSCLC patients who harbored EML4-ALK v3 have been reported to show a longer progression-free survival (PFS) than those harboring EML4-ALK v1 (Lin et al. 2018). This evidence concerns the gene ALK and non-small cell lung carcinoma.